Acasti Pharma (ACST)
$2.93
0.03 (1.03%)
ACST Stock Quote Delayed 30 Minutes
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with the biggest pre-market stock movers traders will want to keep in mind while trading on Tuesday!
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
130.72M
PE Ratio
-3.96
EPS
-0.74
Volume (Avg. Vol.)
2,127
Day's Range
$2.86 - $2.93
52-Week Range
$1.72 - $3.84
Dividend & Yield
N/A (N/A)
ACST Stock Predictions, Articles, and Acasti Pharma News
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, trader! Christmas is almost here but were aren't slowing down as we dive into the biggest pre-market stock movers for Thursday!
ACST Stock Price Predictions: Why One Analyst Sees Acasti Rocketing to $6
After an Oppenheimer upgrade, shares of ACST stock are soaring higher by more than 25%. Why exactly is the investment firm bullish?
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We've reached the halfway point of the week and we're starting it with an overview of the biggest pre-market stock movers for Wednesday!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
The weekend is officially over and that means it's time to jump back into investing with a look at Monday's biggest pre-market stock movers!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, investors! We're kicking off the day with a look at winners and losers of the biggest pre-market stock movers for Wednesday!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off the day with a look at the pre-market stock market movers for Wednesday with the biggest winners and losers.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Get ready for another busy week of trading as we kick off Monday with a look at the biggest pre-market stock movers for today.
Wait for Acasti Pharma Stock to Fall Further Before Buying
The future course of ACST stock depends largely on the company's lead drug candidate, CaPre. Any good news could send the shares higher.
Acasti Pharma Stock Is Only Ideal for a Short-Term Trade
From time to time, ACST stock tends to have massive price spikes. It's too volatile for a long-term position, but may be a trader's paradise.
ACST Stock Alert: 13 Things for Acasti Pharma Investors to Know as Shares Rocket Monday
Acasti Pharma (ACST) stock is on the rise Monday with heavy trading of its shares despite a lack of news concerning the company.
ACST Stock: 13 Things to Know as Acasti Pharma Shares Soar 100%
ACST stock is up more than 100% on Wednesday without any news about Acasti Pharma. Here's what you should know.
Look Anywhere but Acasti Pharma Stock for Opportunity
It doesn't look good for Acasti Pharma stock. If they plan on doubling-down on CaPre, they need more capital. A dilutive equity raise would push shares down further. Even if they do a reverse stock split. Yet, shares aren't guaranteed to hit zero. If their subsequent actions with CaPre pay off, shares could soar as the prospective drug gets back on track.
Acasti Pharma Is a Risky Play After Releasing Disappointing Data
Acasti Pharma stock plunged after the company reported negative trial results. The company's road ahead is filled with risks.
The Reward Is Not Worth the Risk for Acasti Pharma Stock
Acasti Pharma stock collapsed following an unsuccessful Phase 3 clinical trial. But even this major setback isn't the only headwind impacting shares.
First-Mover Advantage Will Benefit Amarin Stock More Than You Think
There’s no reason Amarin stock won’t become a big success with Vascepa, especially with access to millions of patients.
Acasti Pharma Stock Is Bleeding Both Value and Credibility
Acasti Pharma stock jumped higher last year on the potential of Acasti’s krill-oil extract CaPre. But a closer examination of its Phase 3 results suggests not all is well with the company.
There’s No Miraculous Comeback Looming for Acasti Pharma Stock
Acasti's Phase 3 trial of CaPre, aimed at patients with high levels of triglycerides, isn't working out, explaining why the stock is down 69.11% to start 2020. One of the primary causes of concern with the Trilogy 1 Phase 3 trial of CaPre was that there were unanticipated levels of placebo response. Said another way, patients got a cornstarch pill, which of course would be far less expensive than any drug, and had a positive reaction to it.
Sensible Investors Will Ditch Acasti Pharma for Amarin
Acasti Pharma lost $118 million in market capitalization on January 13. That makes Acasti Pharma stock a liability, not a bargain.
Acasti Pharma Stock Has One Last Chance
Acasti Pharma stock plunged after disappointing TRILOGY 1 trial results. TRILOGY 2 results in February mark the company's last chance.
